Immuron (IMRNW)

[Kauri]

Immuron has 4 ongoing Phase 2 trials. 3 Phase trials in NASH in progress, and another blockbuster indication Cdiff (Better product than $MCRB imo)
Of the NASH trials, two of which were selected to be fully funded by the National Institute of Health. Alcoholic fatty liver disease, Non alcoholic fatty liver disease, Pedriatric fatty liver disease.
Dr Arun Sanyal is Chair of NIH NASH Clinical Research network and an Advisory board member to Immuron.
https://www.bloomberg.com/research/stocks/people/person.asp?personId=60481092&privcapId=7687411

If Immuron has positive phase 2 NASH results expect a market cap of $1billion+. That is over 50x the current market cap.
Aside from this Immuron has ongoing sales from Travelan & Protectyn products, dual listed Nasdaq & Australian ASX. Cdiff looks like it works and phase 1/2 trial just commenced, results in 6-9months. This is worth hundreds of millions in market cap right now.
http://www.nextbiotech.com.au/imc-hits-key-milestones-ahead-imminent-nasdaq-listing/
http://www.immuron.com/assets/F105-Immuron-Bioshares-Presentation-July-21-2017.pdf
http://www.immuron.com/investor-centre/analyst-reports/

Stock tickers:
$IMRN on Nasdaq, warrants $IMRNW on Nasdaq
$IMC on ASX, $IMCOB options on the Australian exchange

As you can see from the lack of people on this board, Immuron is currently unheard of & underfollowed, hence massively undervalued.